BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23077112)

  • 1. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
    Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
    J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.
    Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J
    Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral heterogeneity of
    Mitamura K; Yamamoto Y; Kudomi N; Maeda Y; Norikane T; Miyake K; Nishiyama Y
    Ann Nucl Med; 2017 Jan; 31(1):46-52. PubMed ID: 27686469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.
    Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeatability of
    Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
    J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
    Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T
    Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT-PET in previously untreated patients with low-grade glioma can predict their overall survival.
    Belohlavek O; Fencl P; Majovsky M; Jaruskova M; Benes V
    Nucl Med Rev Cent East Eur; 2014; 17(1):7-12. PubMed ID: 24610646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining 3'-Deoxy-3'-[18F] fluorothymidine and MRI increases the sensitivity of glioma volume detection.
    Fernandez P; Zanotti-Fregonara P; Eimer S; Gimbert E; Monteil P; Penchet G; Lamare F; Perez P; Vimont D; Ledure S; Tourdias T; Loiseau H
    Nucl Med Commun; 2019 Oct; 40(10):1066-1071. PubMed ID: 31469809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
    Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC
    J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma.
    Jeong SY; Lim SM
    Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
    J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
    Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
    J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.